Auditory P50 in schizophrenics on clozapine: Improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol

Neuropsychobiology

Volumn 39, Issue 1, 1999, Pages 10-17

  Nagamoto, Herbert T ^a,b   Adler, Lawrence E ^a,b   McRae, Kara A ^b   Huettl, Peter ^b   Cawthra, Ellen ^b   Gerhardt, Greg ^b   Hea, Rebecca ^a   Griffith, Jay ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

3 Methoxy 4 hydroxyphenylglycol; Auditory evoked potential; Clozapine; Homovanillic acid; Schizophrenia; Sensory gating

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; CLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG RESISTANCE; EVOKED AUDITORY RESPONSE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; STIMULUS RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; HOMOVANILLIC ACID; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0032928455     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026553     Document Type: Article

References (62)

1. McGhie A, Chapman JS: Disorders of attention and percept ion in early schizophrenia. Br J Med Psychol 1961;34:103.
2. Venables P: Input dysfunction in schizophrenia; in Maher BA (ed): Progress in Experimental Personality Research. Orlando, Academic, Press, 1964, pp 1-47.
3. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R: Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating and schizophrenia. Biol Psychiatry 1982;17:639-654.
4. Boutros NN, Zouridakis G, Overall J: Replication and extension of P50 findings in schizophrenia. Clin Electroencephalogr 1991;22:40-45.
5. Erwin RJ, Mawhinney HM, Gur RC, Gur RE: Midlatency evoked potentials in schizophrenia. Biol Psychiatry 1991;30:430-442.
6. Judd LJ, McAdams L, Budnick B, Braff DL: Sensory gating deficits in schizophrenia: New results. Am J Psychiatry 1992;149:488-493.
7. Clementz BA, Geyer MA, Braff DL: P50 suppression among schizophrenia and normal comparison subjects: A methodological analysis. Biol Psychiatry 1997;41:1035-1044.
8. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD: Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: Comparison of medicated and drug-free patients. Biol Psychiatry 1983;18:537-551.
9. Adler LE, Gerhardt GA, Franks R, Baker N, Nagamoto H, Drebing C, Freedman R: Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res 1990;31:297-309.
10. Baker N, Adler LE, Franks RD, Waldo MC, Berry S, Nagamoto H, Muckle A, Freedman R: Neurophysiological assessment of sensory gating in psychiatric inpatients: Comparison between schizophrenia and other diagnoses. Biol Psychiatry 1987;22:603-617.
11. Waldo M, Gerhardt G, Baker N, Drebing C, Adler L, Freedman R: Auditory sensory gating and catecholamine metablism in schizophrenic and normal subjects. Psychiatry Res 1992;44: 21-32.
12. Nagamoto HT, Adler LE, Waldo MC, Freedman R: Sensory gating in schizophrenics and normal controls: Effects of changing stimulation interval. Biol Psychiatry 1989;25:549-561.
13. Nagamoto HT, Adler LE, Waldo MC, Griffith J, Freedman R: Gating of auditory response in schizophrenics and normal controls: Effects of recording site and stimulation interval on the P50 wave. Schizophr Res 1991;4:31-40.
14. Nagamoto HT, Adler LE, Hea RA, Hoffer LD, Freedman R: Gating of auditory P50 in schizophrenia: Trait and state related phenomena. Society of Biological Psychiatry Annual Meeting. Biol Psychiatry 1993;33:120A.
15. Kane JM, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
16. Baldessarini RJ, Frankenburg FF: Clozapine: A novel antipsychotic agent. N Engl J Med 1991;324:746-754.
17. Meltzer HY: The mechanism of action of clozapine in relation to its clinical advantages; in Meltzer HY (ed): Novel Antipsychotic Drugs. New York: Raven Press, 1992, pp 1-13.
18. Wu JC, Potkin SG, Ploszaj DI, Lau V, Telford J, Richmond G: Clozapine improves sensory gating more than haldol. New Research Program and Abstracts. APA Annual Meeting, APA Press, Washington, D.C. 1992, p 156.
19. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R: Gating of auditory P50 in schizophrenics: Unique effects of clozapine. Biol Psychiatry 1996;40:181-188.
20. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparisons with fluphenazine. Arch Gen Psychiatry 1992;49: 345-353.
21. Davidson M, Kahn RS, Stern RG, Hirschowitz J, Apter S, Knott P, Davis KL: Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 1993;46:151-163.
22. Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ: Clozapine response and plasma catecholamines and their metabolites. Psychiatry Res 1993;46:139-149.
23. Brown AS, Gewirtz G, Harkavy-Friedman J, Cooper T, Brebion G, Amador XF, Malaspina D, Gorman J: Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: A within-subjects comparison with haloperidol. Neuropsychopharmacology 1997;17:317-325.
24. Ackenheil M: Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 1989;99:S32-S37.
25. Sarafoff M, Davis L, Ruther E: Clozapine induced increase of human plasma norepinephrine. J Neural Transm 1979;46:175-180.
26. Gross G, Schumann HJ: Enhancement of noradrenaline release from rat cerebral cortex by neuroleptic drugs. Naunyn Schmiedebergs Arch Pharmacol 1980;315:103-109.
27. Breier A, Buchanan RW, Waltrip RWII, Listwak S, Homes C, Goldstein DS: The effects of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 1994;10:1-7.
28. Adler LE, Hoffer L, Nagamoto HT, Waldo MC, Kisley MA, Griffith JM: Yohimbine impairs P50 sensory gating in normal subjects. Neuropsychopharmacology 1994;10:249-257.
29. Johnson M, Adler LE: Transient impairment of P50 auditory sensory gating by a cold-pressor test. Biol Psychiatry 1993;33:380-387.
30. Franks RD, Adler LE, Waldo MC, Alpert J, Freedman R: Neurophysiological studies of sensory gating in mania: Comparisons with schizophrenia. Biol Psychiatry 1983;18:989-1005.
31. Baker NJ, Staunton M, Adler LE, Gerhardt GA, Drebing C, Waldo M, Nagamoto H, Freedman R: Sensory gating deficits in psychiatric inpatients. Relation to catecholamine metabolites in different diagnostic groups. Biol Psychiatry 1990;27:519-528.
32. Kang D-Y, Poole J, McCallin K, Fein G, Vinogradov S: Sensory gating deficit in schizophrenia: Relation to catecholamine metabolites. 6th International Congress on Schizophrenia Research. Schizophr Res 1997;24/1,2:234.
33. Adler LE, Rose G, Freedman R: Neurophysiological studies of sensory gating in rats: Effects of amphetamine, phencyclidine, and haloperidol. Biol Psychiatry 1986;21:787-798.
34. Bickford-Wimer PC, Nagamoto H, Johnson R, Adler LE, Egan M, Rose GM, Freedman R: Sensory gating in hippocampal neurons: A model system in the rat. Biol Psychiatry 1990: 27:183-192.
35. Boutros NN, Uretsky NJ, Lui JJ, Millana RB: Effects of repeated cocaine administration on sensory inhibition in rats: Preliminary data. Biol Psychiatry 1997;41:461-466.
36. Salamy A, Salfi M, Fein G: Sensory gating deficit following cocaine exposure in the rat. Neuropsychobiology 1997;36:83-86.
37. Diagnostic and Statistical Manual of Mental Disorders, ed 3. Washington, American Psychiatric Association, 1987.
38. Overall JE, Gorham D: The brief psychiatric rating scale. Psychol Rep 1962;10:799-804.
39. Overall JE: The Brief Psychiatric Rating Scale (BPRS): Recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24:97-99.
40. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr 1987;13/2:261-276.
41. Meltzer HY: Dimensions of outcome with clozapine. Br J Psychiatry 1992;160S17:46-53.
42. Coppola R: Isolating low frequency activity in EEG spectrum analysis. Electroencephalogr Clin Neurophysiol 1979;46/21:101-105.
43. Smith DA, Boutros NN, Schwarzkopf S: Reliability of P50 auditory event-related potential indices of sensory gating. Psychophysiology 1994;31:495-502.
44. Vinogradov S, Solomon S, Ober BA, Biggins CA, Shenaut GK, Fein G: Do semantic priming effects correlate with sensory gating in schizophrenia? Biol Psychiatry 1996;39:821-824.
45. Ward PB, Hoffer LD, Liebert BJ, Catts SB, O'Donnell M, Adler LE: Replication of a P50 auditory sensory gating deficit in Australian patients with schizophrenia. Psychiatry Res 1996;64:121-135.
46. Straumanis JJ, Shagass C, Roemer RA: Influence of antipsychotic and antidepressant drugs on evoked potential correlates of psychosis. Biol Psychiatry 1982;17:1101-1122.
47. Adler LE, Pang K, Gerhardt G, Rose GM: Modulation of the gating of auditory evoked potentials by norepinephrine: Pharmacological evidence obtained using a selective neurotoxin. Biol Psychiatry 1988;24:179-190.
48. Issa F, Gerhardt GA, Bartko JJ, Suddath RL, Lynch M, Gamache PH, Freedman R, Wyatt RJ, Kirch DG: A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia. I. Comparisons with healthy control subjects and neuroleptictreated/unmedicated pairs analyses. Psychiatry Res 1994;52:237-249.
49. Hornykiewicz O: Brain catecholamines in schizophrenia - A good case for noradrenaline. Nature 1982;299:484-486.
50. Van Kammen DP, Gelernter J: Biochemical instability in schizophrenia. I. The norepinephrine system; in Meltzer HY (ed): Psychopharmacology: The Third Generation of Progress. New York, Raven Press, 1987, pp 745-751.
51. Breier A, Wokowitz OM, Roy A, Potter WZ, Pickar D: Plasma norepinephrine in chronic schizophrenia. Am J Psychiatry 1990;147: 1467-1470.
52. Pickar D, Breier A, Hsiao JK, Doran AR, Wokowitz OM, Pato CN, Konicki E, Potter WZ: Cerebral fluid and plasma monoamine metabolites and their relation to psychosis: Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 1990;47:641-648.
53. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Selcshi E, Weintraub SE: Studies of catecholamine metabolism in schizophrenia/psychosis-Part I. Neuropsychopharmacology 1993;8:97-109.
54. Freedman R: Interactions of antipsychotic drugs with norepinephrine and cerebellar neuronal circuitry: Implications for the psychobiology of psychosis. Biol Psychiatry 1977;12: 181-197.
55. Kirch DG, Jaskiw G, Linnoila M, Weinberger DR, Wyatt RJ: Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. Psychiatry Res 1988;25:233-242.
56. Ko GN, Jimerson DC, Wyatt RJ, Bigelow LB: Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. Arch Gen Psychiatry 1988;45:842-846.
57. Bowers MB, Swigar ME, Jatlow PI, Hoffman FJ: Plasma catecholaminc metabolites and treatment response at neuroleptic steady state. Biol Psychiatry 1989;25:734-738.
58. Maas JW, Contreras SA, Miller AL, Berman N, Bowden CL, Javors MA, Seleshi E, Weintraub SE: Studies of catecholamine metabolism in schizophrenia/psychosis. Part II. Neuropsychopharmacology 1993;8:111-116.
59. Van Kammen DP, Kelley ME, Yao JK, Gilbertson MW, Gurklins JA, Inosaka T, Saito H, Peters JL, Sato M: Predicting haloperidol treatment response in chronic schizophrenia. Psychiatry Res 1996;64:47-58.
60. Van Kammen DP, Kelley ME, Gurklis JA, Gilbertson MW, Yao JK, Condray R, Peters JL: Predicting duration of clinical stability following haloperidol withdrawal in schizophrenic patients. Neuropsychopharmacology 1996;14: 275-283.
61. Nagaoka S, Iwamoto N, Arai H: First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment. Biol Psychiatry 1997;41:857-864.
62. Lieberman J, Johns C, Pollack S, Masair S, Bookstein P, Cooper T, Iadorola M, Kane J: Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia: in Tamminga CA, Schulz SC (eds): Advances in Neuropsychiatry and Psychopharmacology. New York, Raven Press, 1991, vol I: Schizophrenia Research, pp 341-349.